WASHINGTON — The Drug Enforcement Agency is reversing a regulation that had been expected to create shortages of morphine and other opioid injectables, according to a DEA letter to drugmakers obtained by STAT.
The DEA dictates the quantity of controlled substances that drug companies are allowed to make. Until this year, those quotas were set annually for Schedule II drugs, such as morphine and other injectable opioids that hospitals regularly use.
In December, the DEA announced that it would use quarterly quotas instead. The goal was to prevent shortages. Some drug manufacturers were not using the full amount of yearly quotas, which the agency said resulted in shortages of those medications. The move to quarterly quotas was meant to stop drug companies from hoarding their quotas.
Click this link for the original source of this article.
Author: John Wilkerson
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.